Optimization of treatment for women with infertility
Abstract
Annotation. Up to 20-25% of women with PCOS are resistant to clomiphene citrate. The aim of the study is to optimize the baseline ovarian response in clomiphene-resistant women to ovulation induction with minimal drug costs. Materials and methods of research: the study included 40 clomiphene-resistant women with PCOS. For women in group I, we used clomiphene citrate 100mg + human menopausal gonadotropin (HMG)37.5 IU / day. Group II received only HMG 37.5 using a low dose escalating protocol. The use of this protocol enables monofollicular growth and a decrease in the risk of multiple pregnancies and, in turn, is the prevention of ovarian hyperstimulation. The results of the study showed that in group I compared with group II, the frequency of ovulation was significantly higher (60% versus 35%). Conclusions. The combined administration of CC + HMG in clomiphene-resistant women with PCOS compared to the use of HMG alone, gives higher ovulation rates and lower financial costs.